Posters

High-irradiance accelerated collagen cross-linking with laser in-situ keratomileusis: 1 year results

Poster Details

First Author: J.Zhang CHINA

Co Author(s):                        

Abstract Details

Purpose:

To assess the effectiveness of high-irradiance accelerated corneal collagen crosslinking (CXL) applied concurrently with laser in situ keratomileusis (LASIK) for one year.

Setting:

Ophthalmic Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing, China.

Methods:

Fifty-six patients were enrolled in this study and divided into two groups: the accelerated CXL treatments (KXL system) with LASIK (Group 1) and only LASIK (Group 2). After LASIK, riboflavin 0.25% was instilled in the residual stromal bed for 90 seconds. After the flap placed in its original position, ultraviolet-A light (30 mW/cm2) was administered for 90 seconds. The postoperative changes in uncorrected (UDVA) and corrected (CDVA) distance visual acuities, manifest refraction spherical equivalent (MRSE), keratometric readings, demarcation line existence, the endothelial cell density (ECD) and corneal hysteresis (CH), corneal resistance factor (CRF) were compared.

Results:

No significant differences in UDVA, CDVA, MRSE, ECD, CH and CRF were found between 2 groups at different time points. There were no statistically significant differences in the keratometric readings preoperatively. However, the mean keratometry in Group 1 was 38.97±1.86, which was obviously lower than that in Group 2 (40.63±1.57) (P<0.05) 1 year after surgery. Increased hyperreflectivity and a demarcation line similar to that seen after CXL were observed in the F-LASIK–CXL eyes one month after surgery. The demarcation line (mean depth 156.58 ±21.37 um) was present in 53 eyes (94.6%).

Conclusions:

Laser in situ keratomileusis with accelerated CXL was safe, effective and predictable. It appears to be a promising method for future applications to prevent corneal ectasia after LASIK treatment.

Financial Disclosure:

NONE